Baricitinib (CAS 1187594-09-7): A Comprehensive Product Introduction
Baricitinib, with the CAS number 1187594-09-7, is a highly significant compound in the field of medicine and pharmaceutical research. This small – molecule drug has shown great potential in treating various diseases and has attracted wide attention from the scientific community.
Chemical Properties
Baricitinib belongs to the class of Janus kinase (JAK) inhibitors. Its chemical formula is C₁₈H₁₉N₇O₂, and it has a molecular weight of approximately 365.39 g/mol. The compound exists as a white to off – white powder. It has certain solubility characteristics; it is sparingly soluble in water but shows better solubility in organic solvents such as dimethyl sulfoxide (DMSO) and methanol. These solubility properties are crucial for its formulation in different pharmaceutical products.
The chemical structure of Baricitinib contains multiple heterocyclic rings and functional groups. The presence of nitrogen – containing heterocycles, such as pyridine and pyrazole rings, contributes to its biological activity and interaction with target proteins. The overall structure is designed to fit precisely into the active site of JAK enzymes, thereby inhibiting their activity.
Mechanism of Action
Baricitinib exerts its pharmacological effects by selectively inhibiting Janus kinases. JAKs are a family of intracellular non – receptor tyrosine kinases that play a key role in the signaling pathways of cytokines and growth factors. There are four known JAKs: JAK1, JAK2, JAK3, and TYK2. Baricitinib is a potent inhibitor of JAK1 and JAK2 with some affinity for TYK2 as well.
When cytokines bind to their receptors on the cell surface, they activate JAKs, which then phosphorylate and activate signal transducers and activators of transcription (STATs). STATs translocate to the nucleus and regulate the expression of genes involved in immune responses, inflammation, and cell growth. By inhibiting JAKs, Baricitinib blocks the phosphorylation of STATs, thereby interfering with the downstream signaling pathways and reducing the production of pro – inflammatory cytokines. This mechanism is the basis for its use in treating inflammatory and autoimmune diseases.
Medical Uses
1. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, pain, and joint damage. Baricitinib has been approved for the treatment of moderately to severely active RA in adults who have an inadequate response to one or more disease – modifying antirheumatic drugs (DMARDs). Clinical trials have shown that Baricitinib can significantly improve the signs and symptoms of RA, such as joint swelling, pain, and morning stiffness. It also slows down the progression of joint damage as measured by radiological assessments.
The efficacy of Baricitinib in RA is due to its ability to suppress the overactive immune response that causes joint inflammation. By inhibiting JAK – STAT signaling, it reduces the production of cytokines such as interleukin – 6 (IL – 6), tumor necrosis factor – alpha (TNF – α), and interferon – gamma (IFN – γ), which are key mediators of inflammation in RA.
2. Atopic Dermatitis
Atopic dermatitis is a common chronic inflammatory skin disease characterized by itchy, red, and inflamed skin. Baricitinib has shown promise in the treatment of moderate – to – severe atopic dermatitis. In clinical studies, it has been demonstrated to improve the severity of the disease, reduce itching, and enhance the quality of life of patients.
The mechanism of action in atopic dermatitis is similar to that in RA. By inhibiting JAKs, Baricitinib reduces the production of pro – inflammatory cytokines in the skin, which helps to alleviate the inflammation and itching associated with the disease. It also modulates the immune response in the skin, preventing the over – activation of immune cells that contribute to the development of atopic dermatitis.
3. COVID – 19
During the COVID – 19 pandemic, Baricitinib has been investigated as a potential treatment for severe cases of the disease. The rationale behind its use is based on the fact that in severe COVID – 19, there is an over – activation of the immune system, leading to a cytokine storm. Baricitinib can potentially suppress this excessive immune response by inhibiting JAK – STAT signaling.
Some clinical trials have shown that the combination of Baricitinib with remdesivir can improve the clinical outcomes of patients with severe COVID – 19. It may reduce the time to recovery and the need for mechanical ventilation in hospitalized patients. However, further research is still needed to fully understand its effectiveness and safety in the context of COVID – 19 treatment.
Other Potential Applications
In addition to the above – mentioned medical uses, Baricitinib is also being explored for its potential in other areas. For example, it may have applications in the treatment of other autoimmune diseases such as psoriasis, systemic lupus erythematosus, and inflammatory bowel disease. The ability of Baricitinib to modulate the immune response makes it a promising candidate for these diseases, which are also characterized by an overactive immune system.
Moreover, in the field of oncology, there is some research on the use of JAK inhibitors like Baricitinib. Since JAK – STAT signaling is involved in cell growth, survival, and angiogenesis, inhibiting this pathway may have antitumor effects. However, more pre – clinical and clinical studies are required to determine its efficacy and safety in cancer treatment.
Preparation Methods
The synthesis of Baricitinib typically involves multiple steps of organic chemical reactions. One common synthetic route starts with the preparation of key intermediate compounds. For example, the synthesis may begin with the construction of the pyridine and pyrazole rings, which are important structural components of Baricitinib.
1. **Ring Construction**: The first step often involves the formation of the heterocyclic rings. This can be achieved through cyclization reactions using appropriate starting materials. For instance, the pyridine ring may be synthesized from acyclic precursors through a series of condensation and cyclization steps. The pyrazole ring can be formed by reacting hydrazines with suitable carbonyl compounds.
2. **Functional Group Modification**: After the ring construction, various functional groups are introduced and modified. This may include the addition of amino groups, hydroxyl groups, and other substituents at specific positions on the rings. These modifications are crucial for the biological activity of Baricitinib. Reactions such as alkylation, acylation, and amination are commonly used for functional group modification.
3. **Final Assembly**: The final step is the assembly of all the intermediate compounds to form the complete Baricitinib molecule. This usually involves coupling reactions between different fragments of the molecule. The reaction conditions, such as temperature, solvent, and catalyst, need to be carefully controlled to ensure high yield and purity of the final product.
Send InquiryReferences
- Author1, Title1, Journal1, Volume1, Pages1, Year1
- Author2, Title2, Journal2, Volume2, Pages2, Year2
- Author3, Title3, Journal3, Volume3, Pages3, Year3